GNX 5086

Drug Profile

GNX 5086

Alternative Names: GNX-5086

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Congenia
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myocardial reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myocardial reperfusion injury(In volunteers) in Netherlands (IV)
  • 15 Aug 2013 Phase-I clinical trials in Myocardial reperfusion injury (in volunteers) in Netherlands (IV)
  • 24 Jul 2013 Regulatory authorities in the Netherlands approve CTA for GNX-5086 in Myocardial reperfusion injury
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top